177276-49-2

Basic information

• Product Name: tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate
• Synonyms: tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate
• CAS NO: 177276-49-2
• Molecular Formula: C14H26N2O4
• Molecular Weight: 286.36724
• Mol File: 177276-49-2.mol

Chemical Properties

• Boiling Point: 375.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• PKA: 7.31±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate(177276-49-2)
• EPA Substance Registry System: tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate(177276-49-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 177276-49-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate is used as a chemical intermediate for the synthesis of pharmaceuticals due to its structural compatibility with bioactive molecules, which can be leveraged to develop new drugs with potential therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate is utilized as a key component in the construction of complex organic molecules, taking advantage of its reactive functional groups to form a variety of chemical products.
Used in Research and Development:
tert-butyl 4-[(2-ethoxy-2-oxoethyl)amino]tetrahydro-1(2H)-pyridinecarboxylate is employed in research and development settings as a probe for exploring new chemical reactions and mechanisms, as well as for the discovery of innovative drug candidates, thanks to its unique structural features and synthetic versatility.

Upstream product

• 623-33-6 glycine ethyl ester hydrochloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 105-36-2 ethyl bromoacetate 
• 459-73-4 GlyOEt*HCl 

Relevant articles and documents

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

AMIDE-SUBSTITUTED ARYL PIPERIDINES

Amide-substituted aryl piperidines derivatives of the following Formulas are provided:(Formulas), in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache, such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.

BIARYL KETONE-SUBSTITUTED PIPERIDINES

Biaryl ketone-substituted piperidines of the following Formulas are provided:, and in which the variables are as described herein. Such compounds may be used to modulate calcitonin gene-related peptide (CGRP) receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CGRP modulation in humans, domesticated companion animals and livestock animals, including headache such as migraine. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such compounds for receptor localization studies and various in vitro assays.

HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (where variables R2, R7, D, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Cgrp Receptor Antagonists

Compounds of Formula I: and Formula II: (where variables R1, R2, R3, R4, A, B, D, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or pr

BENZOXAZINYL-AMIDOCYCLOPENTYL-HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTORS

Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

CGRP RECEPTOR ANTAGONISTS

Compounds of Formula (I), (where variables R1, A, B, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.